Greenwhich Pharmaceuticals Inc&lt;GRPI.O> said it has completed a private placement of its
common stock, generating more than eight mln dlrs in net
proceeds.
    These funds, together with the two mln dlrs in cash
currently held by the company, will be used to complete its
Therafectin rheumatoid arthritis drug development program and
to develop other drugs, the company said.
 Reuter
